Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clifton GT, Peace KM, Holmes JP, Vreeland TJ, Hale DF, Herbert GS, Litton JK, Murthy RK, Lukas J, Peoples GE, Mittendorf Elizabeth A. Clifton GT, et al. Among authors: herbert gs. Clin Immunol. 2019 Apr;201:48-54. doi: 10.1016/j.clim.2019.02.011. Epub 2019 Feb 25. Clin Immunol. 2019. PMID: 30817999 Clinical Trial.
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE. Jackson DO, et al. Among authors: herbert gs. Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305. Oncotarget. 2017. PMID: 27852036 Free PMC article. Clinical Trial.
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA, Byrd K, Vreeland TJ, Clifton GT, Jackson DO, Hale DF, Herbert GS, Myers JW, Greene JM, Berry JS, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwel GL, Peoples GE. Brown TA, et al. Among authors: herbert gs. Cancer Med. 2019 Aug;8(10):4678-4687. doi: 10.1002/cam4.2378. Epub 2019 Jul 5. Cancer Med. 2019. PMID: 31274231 Free PMC article. Clinical Trial.
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X, Wagner TE, Peoples GE. Greene JM, et al. Among authors: herbert gs. Cancer Immunol Immunother. 2016 Apr;65(4):383-92. doi: 10.1007/s00262-016-1809-6. Epub 2016 Feb 19. Cancer Immunol Immunother. 2016. PMID: 26894495 Free PMC article. Clinical Trial.
30 results